Research Summary

Dr. Rebecca Olin is a hematologist who specializes in bone marrow transplantation in adults. Her expertise encompasses treating acute leukemia, myelodysplastic and myeloproliferative disorders (conditions in which the bone marrow makes too many white blood cells) and aplastic anemia (a condition in which the body doesn’t make enough new blood cells).

In her research, Olin has a particular interest in studying how best to treat blood cancers in older patients, some of whom may require a bone marrow transplant.

Olin earned her medical degree from the Perelman School of Medicine at the University of Pennsylvania and was elected to the Alpha Omega Alpha Honor Medical Society. She completed a residency in internal medicine as well as a fellowship in hematology and oncology at the Hospital of the University of Pennsylvania, serving as chief fellow for one year. She also has a master's degree in clinical epidemiology, with a focus on medical decision making, from the University of Pennsylvania.

Education

Amherst College, Amherst, MA, B.A., 1999, Biology
University of Pennsylvania School of Medicine, M.D., 2003
University of Pennsylvania, M.S., 2009, Clinical Epidemiology

Honors & Awards

  • 1999
    Phi Beta Kappa, Amherst College
  • 2002
    Alpha Omega Alpha, early induction, University of Pennsylvania
  • 2002
    Botelho Prize for Excellence in Basic Science
  • 2003
    Dr. Spencer Morris Prize
  • 2005
    American Society of Hematology Trainee Award
  • 2008
    American Society of Hematology Travel Award
  • 2018
    Heme/BMT Value Improvement Program's "Great Save Award," University of California San Francisco
  • 2018
    Health Value Improvement Program's "Best Partnerships Across Initiatives," University of California San Francisco

Selected Publications

  1. Kennedy VE, Ahmed N, Artz A, Bhatt NS, Custatis R, Espinoza-Gutarra MR, Farhan S, Ferguson RJ, Hamilton B, Katz H, Kelly DL, Knight JM, Lee C, Lin A, Lin R, Mohanraj L, Munshi P, Nawas M, Nelson AM, Odstracil S, Olin R, Phelan R, Rentscher KE, Schoemans H, Sung A, Taylor MR, Wood W, Yuen CH, Jayani-Kosarzycki RV Assessing cognitive function in transplantation and chimeric antigen receptor t cell therapy recipients: Expert recommendations from the survivorship, aging and biobehavioral special interest groups of the American Society for Transplantation and Cellular  View on PubMed
  2. Farhan S, Kennedy VE, Espinoza-Gutarra MR, Lust H, Bobillo MSO, Lin AY, Olin RL, Lin RJ, Rentscher KE, Taylor MR, Mohanraj L, Wood WA, Murthy HS, Ahmed N, Dueck AC, Phelan R, Kelly DL, Yuen C, Munshi PN, Schoemans H, Hamilton BK, Lee C, Sung AD Assessing physical function in transplantation and CAR-T recipients: expert recommendations from the survivorship, aging and biobehavioral special interest groups of ASTCT.  View on PubMed
  3. Zeidner JF, Lin TL, Welkie RL, Curran E, Koenig K, Stock W, Madanat YF, Swords R, Baer MR, Blum W, Stein EM, Olin RL, Schiller G, Nichols A, Odenike O, Traer E, Lachowiez C, Duong VH, Hochman MJ, Cai SF, Smith C, Stefanos M, Martycz M, Huang Y, Rosenberg L, Marcus S, Chen TL, Yocum AO, Druker BJ, Levine RL, Borate U, Byrd JC, Mims AS Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.  View on PubMed
  4. Othman T, Lo MM, Andreadis CB, Damon LE, Ferng TT, Gaensler KML, Lee JC, Martin TG, Olin RL, Sayre PH, Smith CC, Logan AC. Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. Leuk Lymphoma. 2025 May 07; 1-4.  View on PubMed
  5. Chehrazi-Raffle A, Zugman M, Ebrahimi H, Shodiya MO, Maldonado E, Othman T, Jaime-Casas S, Carrillo RB, Li X, Pal SK, Tripathi A, Zhumkhawala A, Hoeg R, Oliai C, Olin RL, Dorff TB, Mei M. Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumors. ESMO Open. 2025 May 01; 10(5):105081.  View on PubMed
  6. Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Patel PA, Collins RH, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics T, Deininger MW, Zeidner JF, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Koenig KL, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF. Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial. Blood Cancer J. 2025 Apr 03; 15(1):55.  View on PubMed
  7. Sorror ML, Saber W, Logan BR, Geller NL, Bellach A, Kou J, Wood WA, McCarty J, Knight TG, Runaas L, Johnston LJ, Walston JD, Nakamura R, Jarrett L, Mishra A, Uberti J, Dahi PB, Saultz JN, McCurdy SR, Morris LE, Imus P, Hogan WJ, Nadiminti KVG, Bhatt VR, Olin RL, Maakaron J, Sobecks RM, Wall SA, Mattila D, Protz B, Devine SM, Horowitz MM, Artz AS. Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704. Blood Adv. 2025 Mar 18.  View on PubMed
  8. Munshi PN, Olin RL, Wall S, McCurdy SR, Al-Juhaishi T, Baker J, Bhatt VR, Chokr N, Dahi P, DeFilipp Z, Espinoza-Gutarra M, Farhan S, Gowda L, Hamilton BK, Inamoto Y, Jayani R, Kharfan-Dabaja MA, Lin R, Meyers G, Mishra A, Murthy HS, Nawas M, Rosko AE, Ruiz M, Sorror ML, Sung AD, Carpenter PA, Hamadani M, Artz AS. US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines. Transplant Cell Ther. 2025 Feb 15.  View on PubMed
  9. Hoff FW, Blum WG, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Archer KJ, Patel PA, Collins RH, Baer MR, Duong VH, Arellano ML, Stock W, Odenike O, Redner RL, Kovacsovics T, Deininger MW, Zeidner JF, Olin RL, Smith CC, Foran JM, Schiller GJ, Curran EK, Koenig KL, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Byrd JC, Madanat YF. Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood Adv. 2024 10 22; 8(20):5297-5305.  View on PubMed
  10. H. Ebrahimi, M. Shodiya, E. Maldonado, T. Othman, R. Barragan-Carrillo, X. Li, A. Rock, A. Tripathi, S.K. Pal, T.B. Dorff, A. Zhumkhawala, R. Tetens Hoeg, C. Oliai, R. Olin, M. Mei, A. Chehrazi-Raffle. 701P Multicenter analysis of first-line (1L) regimens (BEP vs VIP) in patients (pts) with non-seminomatous germ cell tumors (NSGCTs) who subsequently underwent high-dose chemotherapy (HDCT). Annals of Oncology. 2024 Sep 1; 35:s540.  View on PubMed
  11. DiNardo CD, Olin R, Wang ES, Skikne B, Rosenthal J, Kumar P, Sumi H, Hizukuri Y, Hong Y, Patel P, Seki T, Duan T, Lesegretain A, Andreeff M. Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies. Cancer Med. 2024 Jul; 13(14):e70028.  View on PubMed
  12. Alex Chehrazi-Raffle, Michael Olufemi Shodiya, Edward Maldonado, Tamer Othman, Hedyeh Ebrahimi, Regina Barragán Carrillo, Xiaochen Li, Adam Rock, Abhishek Tripathi, Sumanta Kumar Pal, Tanya B. Dorff, Ali Zhumkhawala, Rasmus Hoeg, Caspian Oliai, Rebecca L. Olin, Matthew Genyeh Mei. Multicenter analysis of high-dose chemotherapy (HDCT) regimens for the treatment of patients (pts) with recurrent germ cell tumors (GCTs). Journal of Clinical Oncology. 2024 May 29; 42(16_suppl):5039-5039.  View on PubMed
  13. Cai SF, Huang Y, Lance JR, Mao HC, Dunbar AJ, McNulty SN, Druley T, Li Y, Baer MR, Stock W, Kovacsovics T, Blum WG, Schiller GJ, Olin RL, Foran JM, Litzow M, Lin T, Patel P, Foster MC, Boyiadzis M, Collins RH, Chervin J, Shoben A, Vergilio JA, Heerema NA, Rosenberg L, Chen TL, Yocum AO, Druggan F, Marcus S, Stefanos M, Druker BJ, Mims AS, Borate U, Burd A, Byrd JC, Levine RL, Stein EM. A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood Adv. 2024 01 23; 8(2):429-440.  View on PubMed
  14. Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Dunshee DR, Hamidi H, Ott MG, Hong WJ, Andreeff M. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial. Clin Lymphoma Myeloma Leuk. 2024 Jun; 24(6):364-374.  View on PubMed
  15. Beagle AJ, Sunwoo BY, Olin RL, Schwartz BS, Block BL. It's All in the Timing. N Engl J Med. 2023 Sep 07; 389(10):940-947.  View on PubMed
  16. Huang LW, Shi Y, Andreadis C, Logan AC, Mannis GN, Smith CC, Gaensler KML, Martin TG, Damon LE, Boscardin WJ, Steinman MA, Olin RL. Association of geriatric measures and global frailty with cognitive decline after allogeneic hematopoietic cell transplantation in older adults. J Geriatr Oncol. 2023 11; 14(8):101623.  View on PubMed
  17. Lee A, Badgley C, Lo M, Banez MT, Graff L, Damon L, Martin T, Dzundza J, Wong M, Olin R. Evaluation of venous thromboembolism prophylaxis protocol in hematopoietic cell transplant patients. Bone Marrow Transplant. 2023 11; 58(11):1247-1253.  View on PubMed
  18. Tsang M, Bischoff K, Schoenbeck KL, Berry K, O'Riordan D, Fakhri B, Wong SW, Shah N, Olin R, Andreadis C, Vieaux J, Cohen E, Lopez NS, Mannis GN, Rabow M. Value of embedded palliative care: outpatient palliative care and health care utilization for patients with hematologic malignancies. Blood Adv. 2023 07 11; 7(13):3146-3149.  View on PubMed
  19. Jeng MY, Kong D, Rajalingam R, Lin RJ, Olin RL. Lack of disease control remains a major barrier to transplant for older patients with AML. Bone Marrow Transplant. 2023 09; 58(9):1054-1056.  View on PubMed
  20. Saliba AN, Kaufmann SH, Stein EM, Patel PA, Baer MR, Stock W, Deininger M, Blum W, Schiller GJ, Olin RL, Litzow MR, Lin TL, Ball BJ, Boyiadzis MM, Traer E, Odenike O, Arellano ML, Walker A, Duong VH, Kovacsovics T, Collins RH, Shoben AB, Heerema NA, Foster MC, Peterson KL, Schneider PA, Martycz M, Gana TJ, Rosenberg L, Marcus S, Yocum AO, Chen T, Stefanos M, Mims AS, Borate U, Burd A, Druker BJ, Levine RL, Byrd JC, Foran JM. Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Blood Adv. 2023 06 13; 7(11):2360-2363.  View on PubMed

Go to UCSF Profiles, powered by CTSI